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ABST RACT
Inflammatory bowel disease is a group of conditions of unknown etiology,
represented by Crohn’s disease and ulcerative colitis and characterized by the
presence of intestinal wall inflammation. From the first cases described to date,
several studies have been performed to elucidate the cause of inflammatory
bowel disease. Generally, the genetic factors predispose to their occurrence
while epigenetic and environmental factors trigger them. Genetic factors are
mutations of the genes involved in the response and recognition of immune cells
to different pathogens. The most studied epigenetic and environmental factors
are smoking (which predisposes to Crohn’s disease and can be protective for
ulcerative colitis), lack of vitamin D, a diet rich in sugars and low in flavonoids
and fibers. The diagnosis is usually established by endoscopy and biopsy. Recent
technologies can perform live biopsies such as endocytoscopy or confocal laser
endomicroscopy, with an accuracy of 100% compared to classical methods.
Therapy involves several classes of drugs, preferably in association with diet and
lifestyle changes. In case of complications or in non-responsive diseases, surgery
must be considered, as documented for ulcerative colitis that can be cured by
removing the entire colon. The purpose of this review is to present recent findings
on pathology, as well as modern diagnosis and treatment methods for IBD.

Introduction
Inflammatory bowel disease (IBD) is a group of
diseases characterized by the inflammation of the intestinal
wall. This can include a layer (mucosa) or all intestinal
layers, with severe complications such as perforations,
stenosis, bleeding, all of which having a major impact on
the patients' life quality. The economic impact is major due
to the chronic treatment, high hospitalization rates and
recurrence [1-3]. This group of diseases includes Crohn's
disease/ CD, characterized by the presence of transmural
inflammation in any segment of the digestive tract
(clinically expressed as diarrhea with steatorrhea, weight
loss, fever, abdominal pain, etc.), and ulcerative colitis/
UC, pathology located mainly in the colon - most often
rectally, where only the mucosal layer is affected (the main
symptom being the occurrence of bloody stools) [4-7]. A
subtype of inflammatory bowel disease has also been
described, which borrows the characteristics from the CD
and UC, or which cannot fall into either of the two major
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categories. It is classified as unqualified inflammatory
disease [8,9]. Their incidence has increased in recent years,
occurring in both developed and developing countries, with
a different distribution by sex. Crohn's disease is more
common in women and is associated with other
autoimmune diseases/manifestations (irises, irido-cyclitis,
autoimmune thyroiditis, etc.), as well as more frequent
digestive complications (perforation with abscess, stenosis
and fistula formation) [10].
The etiology of the disease remains unknown today,
most likely due to the interaction between immunological
genetic factors (imbalance between anti-inflammatory and
pro-inflammatory factors, with a predominance of the
latter). Other factors are represented by microbiotics
(patients with IBD have a microbial flora with a prosthesis
activity 9-10 times higher than that of healthy individuals),
smoking, a low-fiber diet and a rich processed food diet/
refined food [11,12]. The diagnosis of patients with
inflammatory bowel disease is established through
colonoscopy (which can reveal the appearance of the
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mucosa, the presence of ulcerations, stenosis and, at the
same time, it can procure bioptic material for
histopathological examination), computed tomography or
MRI scanning [13-15]. The current diagnosis by serologic
markers is possible by fecal calprotectin that can
distinguish between irritable bowel syndrome and
inflammatory bowel disease, with the mention that the
fecal level can be influenced by several factors (sex, age,
fiber, the presence of blood in the stool, etc.) [16,17].
The treatment of inflammatory bowel disease has
undergone significant changes since the discovery of the
pathological entity so far, with several classes of drugs
being available for administration (amino salicylates,
corticosteroids, immunological and molecular treatment).
In case of complications, surgical intervention is also
required. A breakthrough was the discovery of the
treatment that can interfere with the TNF pathway, drugs
that can induce the long-term remission. The new
therapeutic approach is based on the direct influence of the
cellular mechanisms that lead to the gastro-intestinal
lesions, the final goal being the healing of the mucosa
(elimination of inflammation with the appearance of
normal mucosal structure) [18-21].
The purpose of this review is to provide an update on
the literature on the causes of IBD, as well as modern
methods of diagnosis and treatment.

Discussion
Pathogenesis
The occurrence of IBD is determined by the interaction
between several factors, such as: genetic, immunological,
environmental and microbiota factors.
Genetic factors
To date, 163 genes have been discovered in patients
with inflammatory bowel disease, of which 30 genes are
common for UC and CD, suggesting the existence of a
common pathological pathway [1]. The NOD-2 gene
encodes a protein that functions as an intracellular receptor
and it structurally resembles the peptidoglycan on the
surface gram-positive and gram-negative bacteria. It helps
the immunogenic cells in the process of autophagy, which
can control the bacterial replication and modulate the
innate and adaptive immune system. It has been observed
that mutations of NOD-2 gene can predispose to the
occurrence of CD [2]. In the study of the pathophysiology
of IBD, it was discovered that autophagy plays a central
role, because it can control the intracellular homeostasis by
degrading cytosolic elements and organs [3], ATG16L1
also appears to be involved in the intracellular process, and
T300A point mutation may predispose to CD. IRGM is a
protein which belongs to the p47 immunity-related GTPase family, its expression on the epithelial and dendritic
cells being often decreased in CD patients [3,4].

Genetic sequencing methods have been used to identify
the IL-23 receptor, in order to establish a possible
association between its mutations and CD [5]. IL-23 is a
pro-inflammatory cytokine that is involved in the
generation of T-helper-17 (Th17) cell, being related to the
pathogenesis of IBD (with gene loci: IL-23R, IL-12B,
JAK-2 and STAT-3) [6,7]. In addition, genetic defects of
IL-10, CARD-9, IL-1R2 REL SMAD3 and other immune
markers also predispose to IBD [4].
Environmental factors
Environmental factors are involved in the onset and
evolution of IBD, among the most studied being: smoking,
a diet rich in processed foods, a diet low in fiber and
flavonoids, drug use, and psychological factors [8].
Smoking is the most investigated environmental factor,
smokers having less often and less severe episodes of UC
[9,10], while chronic disease is a risk factor for
postoperative IBD [11].
The chronic administration of non-steroidal antiinflammatory compounds/ NSAIDs and the large-scale use
of antibiotics have long been considered risk factors for the
development of IBD. It has been shown that the use of
aspirin, regardless of the duration of administration,
rhythm and doses, does not trigger nor impair the condition
of patients with IBD, while the long duration of the
treatment and high doses of NSAIDs have been associated
with relapses [12]. Chronic antibiotics administration can
cause changes in the bacterial flora, predisposing to
infections with potentially pathogenic bacteria which
further lead to colitis. The dose and the period of
administration that would lead to the occurrence of IBD are
not yet determined, remaining to be established in future
studies [13].
The incidence of IBD has increased proportionally with
the level of economic and industrial development, the
confirmation being based on epidemiological and
ecological studies. It is suggested that air pollution can lead
to the increased incidence of IBD (the pathophysiological
mechanism being the increase in the plasma levels of
cytokines and circulating cells) [14-16], while the
increased level of SO2 and NO2 secondary to the burning
of fossil fuels can lead to frequent and severe relapses [17].
Vitamin D plays a role in the pathogenesis of IBD, its
deficiency being considered a risk factor for their
occurrence [18]. The World Health Organization (WHO)
classifies the low intake of vitamin D into deficiency (the
plasma level of 25-hydroxyvitamin D [25(OH)D] being
below 10ng/ml) and insufficiency (in which the level varies
between 10-25ng/ml) [19]. In the digestive tract, Vitamin
D maintains the integrity of the enteric mucosa, by
increasing the number of tight and adherent junctions [20],
E-cadherin and also some components of tight junctions
(such as occludin and claudin) [21]. Another effect of
Vitamin D is to decrease the kinase activity which can
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degrade the myosin chain (due to its binding to the nuclear
receptor) and prevents the degradation of the tight
junctions [22]. Studies concerning the number and the
activity of vitamin D receptors in patients with IBD are
controversial. Thus, there is only one study that finds a
lower number of receptors for vitamin D in subjects with
active IBD than in those who did not suffer from it [23],
while other two studies do not find statistically significant
data between the groups, although they find different
numbers of receptors between the normal and the affected
mucosa [24,25]. In patients with active IBD, there is a
decrease in the expression of Vitamin D receptors,
secondary to the mucosal inflammation mediated by TNFα
and over-expression of CYP27B1 [26]. Binding the
vitamin to the receptor can reduce the activity of claudin-2
(the protein involved in non-specific trans-cellular
permeability and apoptosis), thus being a protective factor
for IBD [27]. This was confirmed by Garg et al., who
administered 10,000 IU of vitamin D daily; after 12 weeks,
the serum levels of this vitamin in patients varied between
40-50ng/ml, being accompanied by a reduction of the
disease activity on the clinical and endoscopic scale [28].
The consumption of flavonoids in food is considered a
protective factor against inflammatory bowel disease, as
they have antioxidant properties by decreasing the amount
of free radicals (causing changes in the microbiota), thus
protecting the mucosal barrier [29]. The antioxidant
properties of flavonoids are favorable in inflammatory
bowel disease, where the free radicals of oxygen are
overproduced secondarily to myeloperoxidase (MPO) and
NADPH system activity [30]. In vivo studies have shown
that most flavonoids reduce colonic MPO levels by
lowering free radical levels, which can be considered a
marker for leukocyte invasion and inflammation [31].
Daidzein, hesperidin and naringenin flavonoids are found
in citrus fruits, bitter fruits and tomatoes, having a
protective capacity on the enteric mucosa by maintaining
the integrity of tight junctions. It is currently considered
that the hyper permeability of the mucosa is the initiating
factor of inflammatory bowel disease [32]. Flavonoids are
also involved in modulating the immune system at the
intestinal level, decreasing the amount of proinflammatory cytokines including TNFα, IL-6, IL-1b via
Epigallocatechin gallate [33].
Quercitin is a flavonoid found ubiquitously in fruits
and vegetables, and causes a decrease in the amount of
macrophages and neutrophils infiltrated in the colon
mucosa of patients with CD or UC, thus decreasing the
activity of the disease [34]. In patients with IBD, severe
dysbiosis occurs with a decrease in the biodiversity of the
colon, the main species found being Proteobacteria [35].
This aspect has been identified in mice with induced
colitis; addition of Quercetin as a supplement appears to be
a favorable factor, by enhancing the biodiversity in the
colon and reducing the inflammation [36].
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Immunological factors
In the pathogenesis of inflammatory bowel disease,
there are changes in the innate and acquired immune
system that led to chronic inflammation, secondary to the
impaired barrier function of the mucosal layer, changes in
the intestinal microbiota and disorders of autophagy [4].
Innate immunity is the first line of defense, being
nonspecific and causing a rapid immune response. Its main
role is to recognize various antigens through the NOD and
TLR receptors, which are found on the surface and in the
cytoplasm of various immune cells (neutrophils, dendritic
cells, monocytes, etc.) [37]. In patients with IBD, there is
an alteration of these two types of receptors. The mutation
NOD2 3020insC 2 predisposes to CD. The mechanisms
presumed to be involved are the lack of response of the
receptor to bacterial lipopolysaccharides [38]. In addition,
the lack of activation of the NF-Kb pathway can reduce the
antibacterial response and will lead to the appearance of
bacterial overpopulation [39,40]. Yet, the lack of inhibition
of the RLR2 pathway leads to an excessively immune
response modulated by T helper cell 1(Th1) [41].
Interleukin-23 plays an important role in the function
of both the innate and adaptive immune system,
intervening early in the response to a pathogen; its receptor
polymorphism is often associated with the presence of both
UC and CD [4].
The acquired immune response is highly specific and it
requires a long time to perform the function. Through the
Th1 cell, large amounts of IL-12 and IFN-γ are produced,
and through Th2 helper cells, IL-4, IL-5 and IL-13 are
released [42]. In CD, there are high levels of IL-2 and IFNγ secondary to increased Th1 cell activity; in contrast, UC
has high serum concentrations of IL-13 secondary to
natural killer-T cell hyper activation [43,44]. The classical
assumption in CD is that the immune response is mediated
by Th1 cells, while in UC by Th2 cells [45]. In vivo studies
have shown that there are similar levels of INF in both
pathologies [46] and that low levels of IL-13 (with
anti-inflammatory function) are similar [47]. Bernando et
al. identified a mixed cytokine profile with predominancy
of IL-6 and the absence of IL-13 in the mucous cell culture
of patients with IBD, which therefore leads to a change in
the classical conception [48]. Th17 cells are capable of
synthesizing large amounts of IL-17, IL-21 and IL-22,
which are the result of the concomitant action of IL-6 and
transforming growth factor β. IL-17A can be found in large
amounts in both CD and UC [49]. The definite role of these
cells in the pathogenesis of IBD remains to be investigated,
especially in that they express surface receptors for IL-23.
Clinical aspects of IBD
Intestinal manifestations of IBD
The characteristic of Crohn's disease is the ubiquitous
involvement of the digestive tract from the oral cavity to
the rectum and anal canal, which can take great variability.
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In classical semiology, a relatively specific pattern is
described - the appearance of abdominal pain with colic,
weight loss and watery diarrhea [50]. Frequently,
abdominal pain occurs prior to the diagnosis of the disease
for several years, its location being in the lower-right
quadrant because the terminal ileum is affected. The
character of the pain is colicky and the intensity is medium
to severe. It can often be confused with appendicitis [51].
Diarrhea may be watery, sometimes with the presence of
bloody streaks, more frequently in case of rectal damage
[52]. Bleeding can also occur many years before the
diagnosis of the disease, with 1-2% of cases with a vital
threat due to high flow [53]. Weight loss is the third major
symptom with a multifactorial cause, presence of chronic
inflammation leading to malabsorption and anorexia.
Chronic disease is often associated with the presence of
fistula and stenosis. The most frequent type of fistula is
between the separate segments of the jejunum, defined as
entero-enteral fistula. Most of them are asymptomatic; if
the diameter of fistula enlarges, the process can lead to an
accelerated intestinal transit with the occurrence of watery
diarrhea. The leakage of intestinal fluid through the vagina
shows the presence of an entero-vaginal fistula. In a few
cases, there may be abnormal communication between the
digestive tract and the urinary tract or even the skin. The
processes located in the digestive tract can be manifested
by colic pain, abdominal bloating or early satiety. For those
placed in the stomach or the duodenum, symptoms vary
depending on the location [51]. In one third of the cases,
patients with CD have anal suffering through the presence
of fistulas, abscesses and fissures [54]. The presence of
anal fistulas is suggestive for a special clinical form, as
these patients have relapses with high and severe
recurrence rates that require prompt therapeutic
intervention [55].
Regarding ulcerative colitis, the symptoms are more
stable, the spread of the disease being exclusively in the
colon. The time until the diagnosis being much shorter than
in the case of CD. The main clinical manifestation of UC
is marked by diarrhea (that occurs most often postprandial
and at night), its severity correlating with the severity of
the inflammation. Regarding the extent of the disease in the
colic region, if the proximal part of the colon is affected, a
large quantity of mucus and blood will come along with the
stool [51]. Massive bleeding with hemodynamic instability
is rare, and can be found in cases of ischemic colitis or toxic
mega colon, accounting for 15% of the patients [56].
Other symptoms present in patients with UC are
abdominal colic pain along with other general symptoms
such as asthenia, fatigue and fever. With the long-term
evolution of the disease, the appearance of strictures and
stenosis can be seen, which can lead to colonic constipation.
It can occur in the distal locations of the disease, when the
stool is associated with lower digestive bleeding [57].

Extra-intestinal manifestations of IBD
IBD is actually a veritable systemic disease, distant
manifestations occurring in addition to the local lesions.
Their incidence varies between 6.2-46.6%, thus affecting
the quality of life of the patient [58]. It is considered that if
one extra-intestinal manifestation appears, the patient is
likely to develop other systemic manifestations over time.
The way they appear in relation to the time of diagnosis of
inflammatory bowel disease can be variable. That is, before
the onset of digestive symptoms (8.7-10% of patients,
according to the study), concomitantly or in the first month
after diagnosis (about 25% of the cases) and in the next two
months after the diagnosis for the rest of the patients [59].
The course of extra-intestinal manifestations is not well
documented. It is considered that antigenic structures
presenting similarities with epitopes of cells in the
skin, synovial capsule or periarticular tissue, can pass
through the intestinal mucosa triggering a local immune
response [60-62]. Patients with CD presenting HLA-A2,
DR-1, DQw5 have a significant predisposition to develop
extra-intestinal manifestations, which are similar to
patients with UC presenting HLADR103 [63]. In the major
histocompatibility complex, there are certain subtypes that
predispose to several extra intestinal manifestations. For
example, HLA-DRB1*0103, HLA-B*27 and HLA-B*58
predispose to articular, dermal and ocular diseases [64,65].
Musculoskeletal manifestations are the most common
form of injury in IBD patients (small and axial joints are
often affected), being present in approximately 40% of the
cases. These include arthritis and peripheral arthritis where
there is no joint damage, as opposed to psoriatic arthritis or
rheumatoid arthritis [66,67]. This form of arthritis is
divided into two subtypes. Type 1 of polyarticular
condition usually is pauciarticular, with fewer than 5 joints
being affected and associated with HLA-B27, B35, and
HLA-DR103 [68]. Large joints (especially the knee) are
damaged, and the treatment administered for intestinal
manifestations can improve and relieve the joint pain [67].
Type 2 polyarticular condition is characterized by the
affliction of more than 5 joints, which does not necessarily
correlate with the evolution of the digestive disease, but is
instead associated with uveitis [69]. In general, arthritis
responds to the NSAIDs (especially COX2), with the
metacarpophalangeal joint being most commonly involved
[67,70].
Axial atrophies include ankylosing spondylitis and
sacroiliitis, which are less common in incidence (only 25%
of patients presenting such symptoms) [71]. In general,
men are more likely to develop such arthropathies,
especially HLA-B27 positive patients [72]. The evolution
is generally progressive and causes significant skeletal
damage without treatment [67]. Sacroiliitis usually occurs
in HLAB27 negative patients and often causes chronic pain
and incapacity of work, which lead to decreased work
59
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capacity and quality of life [73]. In the case of axial
arthropathy, the recommended treatment is methotrexate in
combination with sulfasalazine and azathioprine, or antiTNF antibodies of different generations in refractory cases
[74-76].
Mucocutaneous damage occurs in about 15% of the
patients, the main forms of manifestation being erythema
nodosum, pyoderma gangrenosum, sweet syndrome and
lesions of the oral mucosa [77].
Erythema nodosum is a nodular skin lesion (with
dimensions varying between 0.5-4.5 cm) that is found on
the anterior surface of the lower limbs and less often on the
trunk or face; it usually appears in patients with CD.
Healing is most often possible without scarring. The
diagnosis is made clinically based on the characteristic
appearance [78]. Regarding the treatment, they respond
well to the systemic and/or the local treatment with
corticosteroids (CSs) [79]. In severe cases that do not
respond to the treatment, the suspicion of another cause of
nodules (such as bacterial infections with pseudo
tuberculosis, enterocolic, sarcoidosis, tertiary syphilis or
drug reactions) may be considered. After their exclusion,
there is an upgrade of the treatment with the administration
of CSs in immunosuppressant doses, or the treatment with
anti TNF. It is worth mentioning that the effect of
Infliximab and Adalimumab is superior to other anti-TNF
drugs [80-82].
Pyoderma gangrenosum occurs by the presence of a
nodule or morbillus that grows rapidly in size and affects
the adjacent skin tissue, with the development of a purplish
ulcer at the edges with the elimination of sterile pus [83].
The size of the lesions varies from a few centimeters to the
surface of a limb. Elective locations are on the extension
surface, near the postoperative stoma, but they can occur
anywhere on the body surface [84]. It is often associated
with UC, with damage of the entire colon and affecting
especially woman [85]. The declassifying factor is
represented by skin trauma, including venous punctures or
biopsies [86].
Regarding the treatment of pyoderma gangrenosum,
along with the remission of the colonic manifestations, its
remission also appears. The mild forms respond to the
local injectable treatment with CSs, the local wound
cleaning with wet pads [87]. Sulfasalazine, dapsone or
immunomodulatory drugs are administered in refractory
cases, in the form of azathioprine, cyclophosphamide,
methotrexate, tacrolimus and anti-TNF agents. Most of the
time, healing occurs with residual scars [87-89].
Sweet's syndrome is a rare manifestation associated with
IBD, characterized by a papular-scaly rash on the hands,
feet, torso, or face being associated with fever, arthropathy
and ocular symptoms [90,91]. At the histopathological
examination, large infiltrates with neutrophils appear. It is
often associated with chronic diseases and possible
60

malignancies [67]. The treatment consists in the topical or
systemic administration of CSs [92].
The lesions at the level of the oral cavity appear in
approximately 10% of the IBD cases, determining the
appearance of periodontitis, foot-and-mouth disease, or in
severe cases pyosomatitis vegetans (characterized by
pustular rashes anywhere on the surface of the oral
mucosa) [93]. The treatment requires the administration of
local CSs and/ or an antiseptic treatment [94].
Ocular manifestations occur in 2-5% of the patients
[68,95], being more common in patients with CD than in
UC, especially in subjects younger than 40 years [58,68].
Generally, uveitis and episcleritis (which affects the
anterior chamber of the eye) can advance to the retina and
the choroid, this process being known as panuveitis.
Without a prompt diagnosis, uveitis can lead to vision loss.
The treatment with topical steroids can be life-saving; in
cases of refractory disease, cyclosporine A can be used
[67]. The treatment with Infliximab appears to be the best
solution for the patients with uveitis, sacroiliitis and CD
[96].
Hepato-biliary damage in IBD consists of stricture and
dilatation of the bile ducts, which can lead to intrahepatic
lithiasis, cholecystitis, granulomatous hepatitis or hepatic
steatosis [97]. It occurs more often in patients with UC than
in CD [98]. The dilatations and strictures in the bile ducts
appear before the diagnosis of CD and, once formed, they
lead to altered bile leakage with the appearance of
cholestasis and biliary cirrhosis [99]. The treatment of the
underlying disease does not improve the dilatation and the
stenosis. However, the administration of ursodeoxycholic
acid improves liver functioning. In the case of extra hepatic
strictures, the insertion of stents by ERCP procedure can
be performed. In the final stage of the disease, a liver
transplant is necessary [100].
The diagnosis of IBD
The diagnosis of inflammatory bowel disease is made
by correlating the clinical signs and the symptoms with the
paraclinical investigations (abdominal ultrasound, lower
digestive endoscopy, CT, MRI, etc.) and serological tests,
which are used both as a method of initial diagnosis and to
monitor the disease evolution.
The endoscopic procedures
Endoscopic procedures play a major role in the
diagnosis of inflammatory bowel disease. They are used
for diagnosis/ biopsies (to differentiate between CD and
UC) on the one hand, and for monitoring the disease
evolution (response to treatment and complications) on the
other hand [101]. In patients with IBD upon the initial
evaluation, colonoscopy is performed in order to evaluate
the terminal ileum with the collection of 2 biopsies from 5
different places, including the rectum and the terminal
ileum [102]. It is a simple procedure with minimal side
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effects, which must be limited on patients with severe
forms of colitis or with toxic megacolon. In such cases, it
is possible to perform only rectosigmoidoscopy to obtain
tissue for the histopathological examination [103]. The
classical aspect of UC is the loss of vascularity, erythema
of the mucosa with granular and friable appearance, ulcers,
erosions and pseudo-polyps. This aspect evolves from the
rectum to the proximal level where the intensity gradually
disappears [104]. In CD, the classical lesions are
represented by the presence of discontinuous ulcers, which
give the appearance of paving stone/ cobblestone [105].
In the last decade, the endoscopic equipment has been
developed to highlight the presence of inflammation in the
colonic and intestinal mucosa, being used to better
diagnose/ evaluate the activity of the disease compared to
classical endoscopy [106]. Dye-chromoendoscopy uses
staining agents (methylene blue/ indigo carmine) that are
applied to the mucosa, thus increasing the detective rate of
any changes [107]. This investigation helps detect the early
and various adenomas that could become malignant,
secondary to the inflammation of the mucosa. The
sensitivity of the endoscopic examination is correlated with
the histopathological data [108,109].
Dye less-chromoendoscopy uses several working
systems such as narrow band imaging (a narrow spectrum
of light that is absorbed by hemoglobin from the vessels),
thus leading to a better highlighting of the vascularization
at the level of the organ of interest [110,111]. Compared to
classical endoscopy, it is much better in assessing the
vascularity which appears to correlate with histological
inflammation [112]. The shape of the blood vessels
can predict the risk of recurrence. Patients with vessels
like bare branches have active disease, while in
subjects presenting a honeycomb pattern the disease is
often inactive [113]. Other dye-less chromoendoscopy
technologies are represented by I-scan, blue light imaging,
linked color imaging [110]. The correlation between the
histopathological evolution and the endoscopic appearance
on the I-scan has been recently investigated. The results are
conclusive, with the OE score being largely correlated with
two histological activity scores (Robarts histopathology
index and ECAP for UC) [114]; similar results have been
found in CD [115].
Endocytoscopy is a diagnostic method that allows the
in vivo evaluation of the appearance of the mucosa; by
obtaining virtual biopsies, it can reach up to 50μm in size
[106]. It also correlates 100% with the activity investigated
by classical methods (on Riley score) [116]. Recent studies
have concluded that endoscopy is able to differentiate
between patients with active disease and subjects in
remission, without taking biopsies [117]. Confocal laser
endomicroscopy is an endoscopic evaluation method that
allows the evaluation tissues up to 250 μm [118]. Patients
with remitted UC may show distorted crypts, inflammation

and abnormal vascular pattern [119]. In patients treated
with TNF-alpha inhibitors, the number of affected crypts,
the degree of vascular permeability and the degree of
inflammation compared to the Gupta score could be
assessed, with similarities in 95% of the cases [120].
Upper digestive endoscopy is useful in the evaluation
of patients with CD, which can affect the upper portion of
the digestive tract in 16% of the cases [121]. In such cases,
two biopsies should be obtained from the esophagus,
stomach and duodenum when the damage is suspected
[122]. The results are characterized by the presence of
ulcers, strictures, fistulas and erythema. These damages
may be simultaneous or may occur later, when the
manifestations appear in the distal part of the digestive tract
[123]. In the pediatric population, it is recommended that
the initial assessment be made regardless of the onset of
the disease and whether upper digestive endoscopy is
performed or not [124].
Small bowel capsule endoscopy is a sensitive method
of highlighting small bowel damages, being recommended
for patients with CD [125]. Since its introduction,
technological leaps have been made in terms of image
resolution and capsule size, which has led to their
widespread use [126]. It is a useful investigation especially
in the follow-up of patients, because it is able to diagnose
patients with intestinal ulcers, thus allowing a step forward
in terms of treatment and preventing the risk of intestinal
stenosis and fistulas. At the same time, it evaluates the IBD
evolution and response to treatment, allowing thus an
anticipation of 6 months before the appearance of a new
active form of the disease [127].
Artificial intelligence refers to the ability of computers
to function similarly to the human mind, which can be
useful for the endoscopic diagnosis of IBD [128]. A
Google-based computer aided diagnosis (CAD) system
was used to identify the normal mucosa and the presence
of mucosal healing (Mayo score 1 for 114 patients with
UC), this system recognizing more than 90% of the
processed images [129]. Furthermore, with the help of
artificial intelligence and based on the appearance of red
areas on the endoscopic examination (given by the vascular
pattern), the same team developed a red density score. This
score correlates with endoscopic (Mayo) and histological
activity data, which suggest that the system may intervene
in the subjectivity of the investigator in the evaluation of
the disease [130].
Imaging evaluation
In the IBD, a large number of imaging methods are
used, such as: abdominal plain radiography, barium
contrast studies, computed tomography, ultrasound and
MRI.
Plain radiography is a simple, easy and inexpensive
investigation, being used especially in emergency
departments for the occurrence of IBD complications. The
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digestive perforation induces pneumoperitoneum, while
stenosis on intestinal ulcers appears with hydro-aerial
levels and marked distension of the loops above the
stenotic area [131]. This is most often completed by a spiral
assessment of the abdominal floor such as CT/ MRI or
abdominal ultrasound [132]. Fluoroscopic imaging is a
method of assessing the digestive tract damages in CD and
can be used to investigate both the small intestine and the
colon. Regarding the upper digestive tract, the method of
investigation has recently been replaced by CT, MRI or
enterocapsule [133]. In order to highlight the lesions, it is
necessary to mount a nasal-jejunal probe and to insufflate
the air or methylcellulose (with the formation of a
characteristic double contrast), the appearance of
thickening of the intestine suggesting the presence of
stenosis [134]. Contrast-based enemas can also be
performed, highlighting erosions, ulcers or irregularities in
the colon, with the mention that suggestive images result
only in the presence of double contrast [135].
Computed tomography
Computed tomography (CT) is one of the first methods
of evaluating patients with IBD, due to its availability and
effectiveness. It can diagnose both the local complications
of diseases (fistulas, abscesses, etc.) and the extraintestinal
manifestations (pancreatitis, cholangitis, sacroiliitis, etc.)
[131]. By administering intravenous contrast, several
changes can be observed, such as the thickening of the
mucosa and the mucous layer, the presence of adenopathy/
large nodules obvious in the middle of the affected region
or Comb-sign, which is characterized by a turgescent vasa
recta [136]. The CT can also be used to evaluate the
activity of CD, with a sensitivity of 81% and a specificity
of 88%, being able to detect strictures or damage to the
peri-intestinal tissues [137]. Regarding UC, the results are
moderate, the tomographic evaluation being less correlated
with the activity of the disease (a sensitivity of 74%) [138]
It is more useful in detecting acute complications of the
disease such as toxic megacolon, digestive perforations,
etc. [139]. However, CT has limited utility in monitoring
disease activity in young patients with IBD, as the effect of
ionizing radiation may increase the risk of colon cancer by
7% (in young people) and 16% (in the elderly) [140].
Magnetic resonance imaging
MRI is an imaging diagnostic method that uses nonionizing radiation. Its availability has recently increased,
but it is not frequently used due to the extended time
required for a complete evaluation [131]. It can be used to
evaluate the small intestine and the perineal area
(highlighting lymphadenopathy, fistulas and fissures with
different trajectories), thus becoming the gold standard in
identification of periintestinal complications [141]. Other
signs observed by imaging methods may reveal the parietal
thickening of the small intestine, hyper vascularization,
abscesses and stenosis [142].
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In IBD, the evolution can be investigated by MRI, with
a sensitivity and specificity of over 80% in CD [143], and
over 85% in UC [144]. An activity score was developed by
Rimola-Magnetic Resonance index of Activity/ MaRia
score, in which several parameters are included (intestinal
wall thickness, contrast loading, edema and ulceration)
[145]. The MaRIA score is obtained by quantifying these
parameters at the ileal level, colon and rectum. These
results are correlated with Crohn’s Disease Endoscopic
Index of Severity (CDEIS), so the MaRIA score correlates
with the disease activity and evolution (a score > 7 appears
in the active medium forms, while a score > 11 in the severe
forms of the disease) [145,146].
The treatment of IBD
Several medications are currently available for therapy
of IBD, such as: amino salicylates, immunomodulators,
corticosteroids, biological treatments and small molecules.
Aminosalicylates
Aminosalicylates are represented by sulfasalazine and
other 5-aminosalicylic acid derivatives. Sulfasalazine is a
compound that has been used for over 80 years in the
treatment of IBD [147]. Its mechanism of action is related
to the arachidonic acid system, which causes a decrease in
the amount of leukotrienes and prostaglandins, the
inactivation of reactive and nitrogen reactive species, and
the activation of the aryl hydrocarbon receptor pathway
(which determines the activation of the tissue growth factor
with the accentuation of the tissue recovery) [148,149].
The action of aminosalicylates in UC is documented, as it
can induce the remission of the disease regardless of the
rate of administration (1 or 2 doses daily) [150]. At the
same time, it represents a protective factor for malignant
complications, reducing the risk of colon cancer by 75%
[151]. Regarding CD, studies have shown that the oral
administration of aminosalicylates does not induce
remission nor it maintains it [152]. However, their
administration for more than 1 year has led to decreased
medical costs of hospitalization for severe forms or surgery
[153]. Mesalamine, when administered in high doses,
induces remission of the disease (in patients with moderate
and severe forms of CD) and prevents the administration
of steroids [154].
Adverse reactions caused by aminosalicylates are
moderate (headaches, abdominal pain and diarrhea) and
can be easily managed [148].
Corticosteroids
Corticosteroids (CSs) have the property of inducing the
remission of inflammatory bowel disease through a
systemic anti-inflammatory effect. It is mediated by the
binding of the steroid molecule to the nuclear receptor,
which results in low transcription of genes responsible for
the pro-inflammatory proteins and stimulation of genes
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that are responsible for the anti-inflammatory effects [155].
In IBD, CSs are recommended for patients who have been
receiving mesalazine for more than 4 weeks for moderate
forms, and only after the complete cycle of the treatment
[156]. The systemic route of corticosteroid administration
can cause different effects: diabetes, hypertension,
immunosuppression predisposing to infections with
opportunistic germs, osteoporosis, etc. [157,158]. In the
case of long-term use, corticosteroid dependence may also
occur, being defined by the use of high doses of steroids
for the same or no effect [159]. The second generation of
corticosteroids (butensonide) has a higher safety profile
than the others, being administered orally with gradual
release in the terminal ileum and ascending colon (the pHdependent capsules decreasing its systemic effects) [160].
For mild or severe forms of CD, with lesions placed on the
ascending colon or the terminal ileum, 9 mg daily therapy
for 8 weeks is generally effective [156].
Immunomodulators
Thiopurines
T-lymphocytes are an important element in the
pathogenesis of inflammatory bowel disease, penetrating
the mucosa and releasing pro-inflammatory cytokines,
which further cause local lesions. Thiopurines, such as
azathioprine and mecaptopurine, inhibit T-lymphocytes
proliferation and activation [161]. In an observational
study, thiopurines can maintain the remission of UC for 7
years in 43.8% of the cases, and prevent colectomy in 88%
of the cases [162]. The effect of azathioprine is favorable
in both UC and CD, reducing the rate of hospitalization and
preventing postoperative complications [163-165]. In the
case of CD, azathioprine determines the remission of the
disease and reduces the need for steroids to no dose for 60
months [166]. However, the side effects of thiopurines are
multiple and can be life-threatening. Such adverse effects
are represented by the suppression of bone marrow, hepatic
cytolysis with hepatitis [167] and gastrointestinal disorders
[168]. For this reason, 39% of patients discontinue the
treatment with thiopurine within the first 3 months [169].
Methotrexate
At low doses, methotrexate causes the inhibition of DNA
synthesis, as well as the lowering of the plasmatic levels of
IL-1, IL-2, IL-6, IL-18, all this leading to a decrease in the
inflammatory response and the activity of T-lymphocytes
[170]. Administration of 25mg methotrexate/week can
maintain the remission of CD for 40 weeks, the remission
being noted in 72% of the patient after 3 months of
treatment [171]. Methotrexate side effects are represented
by nausea, vomiting, fatigue, and immunosuppression
which can lead to atypical pneumonia. Regarding UC,
methotrexate has not been proven its efficacy as an
inductor treatment [172].

Calcineurin inhibitors
The calcineurin inhibitors used in the treatment of IBD
are cyclosporine A and tacrolimus, which inhibit the NEAT
system by binding to specific receptors (Cyclophilin A and
FK binding protein 12) [173]. In addition, tacrolimus
induces macrophage apoptosis and inhibits the release of
pro-inflammatory cytokines IL-12, IL-23 and TNFα [174].
Cyclosporine A is indicated in severe forms of UC
refractory to treatment, by administration of 4mg/kg.
Remission can be achieved in 80% of the patients over 8
days, relatively similar results being obtained with a dose
lower than 2mg/kg [175,176]. Regarding the association of
CSs with cyclosporine A in the relapses of patients with
CD, no advantages were observed compared to the CSs
monotherapy [177].
In comparison with cyclosporine, tacrolimus has a 1020-time stronger effect in vivo and 30-100 times in vitro
[178]. It has the ability of inducing the remission of UC
and maintaining it for more than 30 days in 70.4% of the
cases [179]. At the same time, it prevents the surgical
therapy in the evolution of the patients, with rates of up to
69% at 1 year from the beginning of the treatment [180].
Regarding the effect of tacrolimus in CD, the data are
controversial; the remission rates is obtained on about
44.3% of the patients, regardless of the route of
administration (topical or systemic) [181]. The side effects
of tacrolimus are kidney and liver damages, predisposition
to infections and hyperkaliemia. The maximum benefit can
be obtained by monitoring the plasma level of the drug,
which must be maintained at concentrations between 1015ng/ml [182].
Biologics
Biological treatments target either pro-inflammatory
cytokines (TNFα, IL-12, IL-23) or several proteins
(integrins). TNFα is a cytokine involved in inflammation,
apoptosis and cell proliferation; the overexpression of
TNFα gene can lead to various autoimmune diseases [183].
Treatments with anti-TNFα monoclonal antibodies are
useful in non-responding patients to immunomodulatory
therapy with CSs, or in patients who become dependent on
CSs [147]. Infliximab has been shown to be effective; after
54 weeks of treatment, rates of colo-rectectomy and
hospitalization decrease by 7% for the patients with mild
and severe forms of UC [184]. In CD, 5mg/kg of
intravenous infliximab led to remission in 68% of the
patients, and the fistula cure rate was 55% [185].
Golimumab, a human monoclonal antibody against TNFα,
determines a better cure rate than placebo [186,187], so it
is currently used in patients with severe forms of UC and
non-responding to conventional treatment [188,189].
Although TNFα plays a central role in the pathogenesis of
inflammatory bowel disease (its inhibition being very
important for successful treatment), there are patients who
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do not respond to treatment in 40% of the cases, and
between 23-46% of subjects lose their response to
treatment over time [190]. This leads to several strategies
of improving the therapeutic efficacy, such as de-escalation
after remission, or increasing the period between
administrations [191].
IL-12 and IL-23 are pro-inflammatory cytokines
released in the antigen recognition reaction by the immune
cells, being involved in UC and CD in the onset and
maintenance of intestinal inflammation [192]. Structurally,
IL-12 and IL-23 have two components, p40 that is a
common component, and p35 for IL-12 or p19 for IL-23.
Monoclonal antibodies have been developed, with
ustekinumab binding to the common component p40. This
component prevents cytokine from binding to its own
receptor on the surface of T/ NK cells, thus leading to the
inhibition of inflammation. Randomized studies have
shown the effectiveness of ustekinumab in moderate and
severe cases of UC and CD [193]. By administering it for
8 weeks, the endoscopic activity score of the disease
decreased by 2.8 points compared to the control group (p =
0.012) [194]. Mirikizumab is a monoclonal antibody
against the p19 subunit of IL-23, which leads to the clinical
remission of the disease by administration of 200 mg
for 12 weeks. No major adverse reactions were observed
during the administration of these monoclonal antibodies
for treatment induction and/or maintenance [195].
Integrins are surface cell receptors that intervene in the
leukocytes localization by binding them to specific cellular
receptors, called cell adhesion molecules. Integrin a4b7 is
present in the intestine and lymphoid tissue, which allows
the migration of leukocytes in the mucosa and adhesion to
this level. Patients with inflammatory bowel disease have
a high number of such receptors [196]. The accumulation
of inflammatory cells aggravates local inflammation by the
massive release of INF-γ, TNF-α, IL-17A, which decrease
the tissue repair system [197]. Anti-integrin treatment
blocks the effect of integrin on endothelial cells/ leukocytes
at the time of contact with the intestinal mucosa.
Vedolizumab is a monoclonal antibody that binds
to α4β7, thus preventing the migration of lymphocytes
to the intestinal receptor and further reducing the degree of
inflammation. Phase 3 studies have shown that
vedolizumab can maintain and induce the remission of the
disease with a high tolerance for patients, without the risk
of immunosuppression. The drug has a high selectivity for
receptors [198,199], being indicated for patients with
moderate or severe UC/CD that do not respond to
conventional or anti-TNFα therapy [200]. If the remission
of the disease is not achieved, it can be associated with
calcineurin or TNFα inhibitors [201,202].
Etrolizumab is an ultra-selective monoclonal antibody
that inhibits the β7 subunit of the integrin α4β7 and αEβ7
[197], thus leading to the remission of moderate or severe
forms of UC and CD [203].
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Biological agents are highly effective, selective and
have a low toxicity. Such agents are expensive and the
patients may be intolerant or unresponsive to the treatment
if used improperly, due to JAK inhibitors that block
multiple intercellular or intracellular signaling pathways.
However, it can be a solution for unresponsive patients
[147]. Tofacitinib is an inhibitor of JAK1 which is found
ubiquitously and JAK3 that is found in hematopoietic cells,
being useful in the treatment of severe forms of UC [204].
It is able to induce remission after 8 weeks of treatment,
the rate of remission in the investigated group being 18.5%
higher than in patients in the control group. The best rates
of remission of the disease were obtained by administering
10 mg on a daily basis. Long-term side effects are still
under investigation; however, thrombosis, infections or the
reactivation of varicella-zoster virus may occur in the acute
period [205].
Another molecule which was developed and with
similar results and uses is filgotinib, which can be
administered orally in CD with satisfactory results [206].
If administered in 45 mg doses for moderate/ severe cases
of UC, upadacinib may induce the remission of the disease
and improve endoscopic score, but with the risk of
developing pulmonary embolism or deep vein thrombosis
[207].
Novel Therapies
In refractory or unanswered cases, new methods of
inducing the remission of the disease have been developed,
including apheresis, cell therapy or exome therapy. They
are the starting points for possible new therapeutic methods
[147]. Apheresis can reduce the local inflammatory
response by isolating and absorbing leukocytes from
peripheral blood [208], which can induce the remission of
the disease in UC. It has a better efficiency than in the case
of CSs administration [209]; in some patients, mucosal
healing can be achieved with a low rate of incidence of
adverse reactions [210].
Changing the intestinal microbiota
In patients with IBD, there is an imbalance between
pathogenic and potentially pathogenic bacteria, which
determines an abnormal immune response. Several data
suggest that changing the microbiota can improve
symptoms and even remit the disease [211]. The antibiotic
therapy can be considered a future treatment option, by
changing the bacterial flora. Administration may induce
some additional beneficial effects, such as the reduction of
the risk of postoperative complications [212,213]. In
patients with CD, the administration of the antibiotic
treatment as the inductor of the remission may lead to
modest results, inducing a degree of remission of the
disease but without marked symptomatic improvement.
Consequently, this class of drugs is not indicated in
initiating and maintaining the remission of IBD [214].
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Administration of probiotics (living microorganismslactobacillus and bifid bacterium), prebiotics and
symbiotics have a beneficial effect in IBD, especially in
UC. Symbiotics can induce and maintain the remission of
the disease better than pro and prebiotics [215], and their
association with conventional drugs leads to a superior
effect compared to single drug administration [216]. The
regular consumption of kefir containing lactobacilli can
increase the quality of life of patients with IBD [217].
The effects of probiotics are demonstrated especially in
UC. As for CD, the effects of the probiotic therapy are
controversial [218].
Fecal material transplant (FMT) is a procedure in which
the feces of a healthy donor are transferred to a patient with
IBD, in order to improve the intestinal microecology
and thus to improve/cure the disease [147]. Fecal
transplantation is efficient in the treatment of refractory
and recurrent IBD with a success rate of up to 90% [219].
The Australian Consensus approved the transplantation of
fecal matter in moderate forms of UC for the first time, in
order to induce remission of the disease, the efficiency
being superior to placebo after 7 weeks of administration
[220]. The main advantage of FMT is the restoration of a
quasi-normal ecosystem in patients with IBD, by
administration of a wide and varied spectrum of bacteria.
The higher the success rate and response to treatment of the
disease, the greater the variety of bacteria from the donor
[221]. The method of administration of transplant material
can influence the efficiency of the treatment. The best
results are obtained by administering fecal matter through
enemas, being able to administer larger quantities and in a
more efficient way (than the administration by superior
route or by colonoscopy) [222]. One of the shortcomings
of fecal transplantation is the inability to determine longterm efficacy, because studies have not monitored patients
for more than 1 year [223]. There may be some side effects
such as bloating and diarrhea [224], or other reactions
related to the oral route of administration: aspiration
pneumonia and the perforation of the colon [225].
Stem cells have the ability of differentiating and
proliferating on a particular cell line. They have the ability
of repairing damaged tissue in IBD, helping to restore the
mucosal barrier. The cells involved in the
pathophysiological mechanisms of UC and CD are related
to hematopoietic/ mesenchymal line, as well as to intestinal
mucosa that can be restored (reducing inflammation and
inducing the remission of the disease) [147].
Hematopoietic stem cells have the ability of migrating
to damaged tissues, helping them with the restoration and
regeneration process. In IBD, the cells used for transplant
are harvested from the bone marrow, umbilical cord or
peripheral blood with CD34 surface marker [226]. Several
studies have been published on this topic. For example, 82
patients with CD received stem cell transplants, which led

to remission and relief of symptoms in 68% of patients,
with a disease-free period of 6-174 months [227]. At the
same time, stem cell transplants resulted in a 38%
reduction in the need for steroids in these patients after 3
months, half of all subjects achieving mucosal healing
[228].
Regarding the safety of this new method of treatment,
literature data show that patients need maintenance or
rescue treatment after 1 year of treatment [229]. About
80% of the patients reach the initial stage of the disease or
require a new transplant after 5 years [230]. All this are
associated with an increased risk of severe
immunosuppression, leading to viral infections, sepsis and
pneumonia. For this reason, it is considered that autologous
transplantation may be useful in the refractory forms of the
disease that do not refer to other therapeutic methods [231].
ABX464 is an antiviral drug that can be used as the only
treatment for HIV patients [232]. It may increase the
expression of miR-124 and may inhibit the immune
response of patients with IBD [233]. By administering 50
mg/ day of ABX464 orally for 8 weeks, an improvement in
the endoscopic appearance can be achieved, without severe
side effects [234].
IL-10 is a pro-inflammatory cytokine that may be
interfered, decreasing UC and CD activity but leading to
long-term anemia or thrombocytopenia [235]. AMT101 is
a chimeric protein fragment binding to the IL-10 receptor
in lamina propria, which appears to stimulate/ exert antiinflammatory proteins without side effects [236].

Conclusions
From the initial description of inflammatory bowel
disease, many pathophysiological mechanisms have been
elucidated and presented. These mechanisms can be
interfered with by different therapeutic classes of drugs. To
note, such mechanisms are induced by several (genetic,
environmental, immunological, and microbiotics) factors,
which are interdependent and should not be addressed
separately. This means that IBD should be considered a
multifactorial systemic disease, which must be treated by
complex therapeutic methods.
The diagnosis must take into account the digestive
manifestations, including their complications, as well as
the extradigestive manifestations, which may be difficult
for the clinician to detect.
The treatment must be multimodal on all possible
levels, by gradually initiating an appropriate therapy. A
treatment upgrade may be necessary in the case of nonresponsive forms, and even a rescue therapy when lifethreatening complications occur.
Finally, a healthy lifestyle without exposure to stress,
pollutants, with a rich diet in flavonoids, regular exercise
can help the patients relieve their symptoms and induce/
maintain the remission of the disease.
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